

1 A scoping review identifying interventions that have been tested to
2 optimise the experience of people from ethnic minority groups
3 receiving systemic anti-cancer therapy (SACT)

4

5 **Abstract**

6 Disparities have been identified in many aspects of the cancer care pathway for people from minority
7 ethnic groups (MEG). Adherence to systemic anti-cancer therapies (SACT) has been shown to impact
8 morbidity and mortality and therefore unequitable experiences can have a detrimental effect on
9 outcomes. The purpose of this scoping review was to identify interventions that focused on
10 improving the experiences and clinical outcomes in people from MEG receiving SACT treatments.

11 A comprehensive search was performed using three electronic databases (Medline, Embase and
12 Cinahl). Standard scoping review methodology following PRISMA guidelines was used. Studies were
13 included that assessed interventions to improve MEG patients experience with SACT. Independent
14 duplicate screening, study selection, data extraction and quality assessment was undertaken. Results
15 of the studies were assessed using a published equity framework.

16 Nine studies were included after exclusion criteria were applied. Studies described six digital, two in
17 person and one hybrid interventions employing different research methodologies, ranging from
18 randomised controlled trials (RCT's), feasibility study and mixed methods studies. The majority of
19 interventions in this study were delivered remotely, using digital platforms such as websites,
20 recorded educational training materials as well as social media. These interventions were conducted
21 in the USA and primarily targeted early breast cancer patients from African American backgrounds.

22 This scoping review showed that there has been a very small number of studies investigating
23 interventions to optimise SACT treatment experiences in people from MEG. **We found evidence of**
24 **interventions incorporating the equity domains that reported improved patient engagement and**
25 **experience.** This new knowledge will help to implement future SACT interventions, addressing health
26 inequities across the cancer continuum.

27

28

29

30

31

32

33

34

35

36

1
2
3
4

5 **Introduction**

6 Cancer is the leading cause of mortality worldwide and over the past two decades, innovations in drug
7 treatment have improved overall survival [1]. Improvements are not equally applicable to all patients,
8 with significant differences in cancer mortality rates between people from minority ethnic groups
9 [MEG] [2]. Although considerable progress has been made in the last decade describing cancer health
10 disparities amongst people from MEG, inequalities still exist, which was further highlighted during
11 COVID-19 pandemic. [3]

12 The specific health barriers that people from MEG are still facing today are multifactorial and are
13 influenced by patients' demographics (age, gender, insurance, social class, race, and geography),
14 language and acculturation, attitudes, and family and cultural contexts. [4] **Persistent lack of resources**
15 **to protect and improve health, influences how people from MEG perceive healthcare services and are**
16 **underpinned by intermediary, social and structural determinants of health.** [5] At present in the United
17 Kingdom (UK) there is limited research evidence to indicate what types of intervention would prove
18 most effective among MEG and marked differences among the UK population exist mainly due to lack
19 of preventative care in general. [6]

Commented [A1]: Unsure about this sentence...

20 With the World Health Organisation's declaration, post COVID-19 public health emergency, attention
21 has shifted to the prevention and treatment of other communicable diseases as well as non-
22 communicable diseases, and the critical contributions of medicines globally. Cancer incidence is
23 expected to rise significantly through 2050, particularly in lower-income countries, with an increase of
24 over 12 million new cases annually. The growing disease burden underscores the urgent need for new
25 treatments to enhance survival and quality of life. [7]

26 Drug treatments for cancer are available in many forms; oral, intravenous, sub-cutaneous and intra-
27 thecal [1]. There has been a rise in the use of oral therapies in the last 10 years requiring administration
28 and correct dosing to be managed by the person with cancer, over long periods of time. Oral therapies
29 are convenient for the patient as they reduce frequent visits to cancer centres to receive intravenous
30 drugs and enables patients to self-manage their treatment. However, patient adherence to oral
31 anticancer drugs is an emerging issue in modern oncology. **A systematic review by Greer et.al. reported**
32 **that patients' adherence to oral SACT can be as low as 46%.** [8] A further study investigated rates of
33 non-adherence between people from a White British background and ethnic minority breast cancer
34 survivors finding that women from minority ethnic groups had a significantly higher risk of non-
35 adherence than women who were from a White British background (odds ratio = 1.50, p = 0.03). [9]
36 Patients are taking medications for prolonged periods of time for certain cancers and are expected to
37 notice and report serious side effects to their medical team. Without tailored patient education, it is
38 difficult to achieve maximum benefit for the individual patient and consequently for the whole health
39 system.

40 Statistics in the UK show that more than a third (36%) of all cancer cases are diagnosed in people
41 aged 75 and over, and with age the number of comorbidities requiring medication also rises [10,11].
42 Patients on multiple medications may struggle to adhere to Systemic Anti-Cancer Therapy (SACT)
43 treatment regimen and there are many factors influencing non-adherence to oral anti-cancer drugs,

1 such as socioeconomic-related factors, healthcare system-related factors, patient-related factors,
2 disease-related factors, and therapy-related factors [12]. Non-adherence to medications negatively
3 affects efficacy, safety and costs of therapies. Evidence suggests that there is a social gradient to non-
4 adherence, as belonging to an ethnic minority might have a negative impact on adherence to
5 medications, which is closely related to the level of health literacy. [13]

6 Health literacy is defined as “the degree to which individuals can obtain, process and understand the
7 basic health information to make appropriate health decisions”. [14] It is known that high health
8 literacy is associated with increased patient engagement, better self-management and essentially
9 improved health outcomes [12]. There is evidence to suggest that healthcare professionals should be
10 addressing unconscious biases when identifying patients with low literacy levels rather than targeting
11 knowledge deficit .[15] Implicit biases are unconscious attitudes and beliefs, that influence people's
12 behaviour and interracial interactions often may produce mistrust in healthcare.[16] While there are
13 increasing efforts to explore how treatments can be improved for people from MEG in Western
14 societies, a holistic global review of this pressing matter does not yet exist. This may, in part, be due to
15 the tendency among researchers to focus on specific countries, diseases and impacted communities
16 [17]. The intersectionality of ethnicity with other factors such as advanced age, health and digital
17 literacy compound the inequity.

18 The present review draws together available evidence on the types of interventions used to optimise
19 cancer patients from MEG treatment with systemic anticancer therapy (SACT). The findings from this
20 review will inform the design of potential interventions, to improve adherence and subsequent
21 outcomes to achieve equitable cancer care.

22 The review was guided by three research questions that supported the aim of identifying
23 interventions that have been used to optimise SACT treatment in patients of different ethnicities.

24 1. How were interventions conducted in their chosen patient population?
25 2. Have these interventions improved patient experience, safety and efficacy of treatments?
26 3. What were the key equity dimensions related to these interventions?

27

28 **Methods**

29 Protocol and registration

30 This scoping review followed the Arskey and O'Malley methodological framework for scoping
31 reviews [18] and the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension
32 for Scoping Reviews (PRISMA-ScR) checklist criteria [19] [See Appendix 1]. The study protocol was
33 registered on Open Science Framework (registration DOI 10.17605/OSF.IO/KFS7H).

34

35 Search strategy

36 The population, intervention, comparison, outcome (PICO) framework [20] was used to develop the
37 search strategy. Following this, a comprehensive search was performed from database inception until
38 June 7th, 2023 with the following databases: EMBASE (Ovid), MEDLINE (Ovid) and Cumulative Index
39 to Nursing and Allied Health Literature (CINAHL). The search strategies used MESH terms and key
40 words outlined in Appendix 2. The reference lists of the 7 selected publications were searched for
41 additional sources and additional 2 publications were identified. A combined initial screening of title
42 and abstract for eligibility was then conducted using a priori study protocol. Following the initial
43 screening at the title and abstract level, a second researcher (author LS) verified 10% of exclusions
44 against the inclusion criteria. Subsequently, the remaining publications that met the inclusion criteria

1 underwent full-text screening for eligibility. To ensure improved accuracy, 100% of included and 5%
2 of excluded documents were checked by author LS, and discrepancies were resolved via consensus.
3 The search was re-run on the 6th of August 2024 with the following databases: EMBASE (Ovid) and
4 MEDLINE (Ovid); no new studies were identified.

5

6 Eligibility criteria

7 Eligibility criteria are summarised in Table 1. The population of this study was defined as people from
8 MEG, classified based on a combination of social, cultural or linguistic characteristics that would
9 distinguish them from the majority of the population in the United Kingdom (UK). All cancer types
10 were included in the study and the types of interventions that were considered ranged from
11 educational programs, behavioural interventions, changes in healthcare delivery models to
12 pharmacological adjustments. The delivery of interventions could be provided by any type of
13 healthcare provider and the setting for interventions was not limited to clinical, online or
14 community-based services. The outcome of patient experiences was defined by numbers of health
15 interactions or surveys capturing satisfaction within interventions, that influenced patient
16 perceptions to various outcomes as defined in Table 1.

17 [Table 1] PICO search strategy

Eligibility criteria	Population	Intervention	Comparison	Outcome
Inclusion criteria	Adult (over 18 y) People from MEG Receiving SACT	Studies including interventions to better manage systemic anti-cancer therapies (SACT) Studies exploring implementation of interventions Study types included in the review were evaluation studies , randomised/non-randomised controlled trials and all observational studies.	Usual care/No intervention	Adherence and compliance to therapy (SACT) defined by either patient following prescribed treatment regimen or treatment completion. Quality of life (measured using QOL assessment tools) Adverse events to treatments Symptom management Self-efficacy Barriers and limitations to implementation of interventions Patient experiences of intervention delivery Healthcare utilization, survival rates, cost-effectiveness, disparities in care
Exclusion criteria	Patients under 18 years old	Studies including opinion pieces, literature and systematic reviews, non-English studies, conference abstracts Studies not describing an intervention Not retrievable studies	N/A	N/A

18

1 Key characteristics of the interventions described the following parameters in these studies: author,
2 year, country, intervention type, objectives, methods, sample demographics, outcomes, dimensions
3 of accessibility to interventions, quality assessment of interventions.

4 Selection of sources of evidence

5 The RefWorks bibliographic software package was used to manage all the references. Potential biases
6 were considered during the selection process. The inclusion of a specific population in the study can
7 have a dramatic impact on the conclusions for the effectiveness of a treatment. [21] It is known that
8 racial disparities among cancer patients are a widespread phenomenon affecting health outcomes of
9 this group of patients, so by selecting this population could introduce a spectrum bias and
10 publication bias. To avoid these biases two researchers conducted the selection process, including
11 studies with positive and negative research findings. The reviewers verified that the studies met the
12 eligibility criteria and addressed our research question.

13 Data charting process

14 Studies that met inclusion criteria were summarised qualitatively, and the summary of the results
15 reported according to the Arskey and O'Malley guidelines [18].

16 Two Excel data extraction forms were used to organise the review process:

- 17 1. Data were extracted from articles and charted using the unique chart adapted from the
18 Template of intervention description and Republication checklist [Appendix 3] [22].
- 19 2. The methodological quality of the empirical studies was critically appraised by two
20 researchers using the Mixed Methods Appraisal Tool (MMAT) [Appendix 4] [23].

21 Participant and design characteristics of the studies are summarised in table 2. Following extraction
22 of the data, studies were summarised in table 3. and included the following details: author, year,
23 country, intervention, methods, sample size, study population, cancer type and specific study
24 outcomes.

25 Data synthesis and reporting

26 Data were synthesized using the equity framework adapted from Sayani et al. [5]. To assess
27 accessibility dimensions of the interventions there were five parameters used in the process:
28 approachability, acceptability, availability, affordability, and appropriateness of the studies.
29 Interventions were mapped against the result section of the framework using five dimensions and
30 the summary is provided in figure 2. The features listed under each dimension in Figure 1 were based
31 on Sayani et.al work, as well as clinical practice and early conversations with the patients and
32 partners in this study.

33 Only the data relevant to SACT was extracted from the original equity framework, which was
34 designed to assess effectiveness of interventions in accessing lung cancer screening amongst
35 targeted priority populations. Table 4 contains 5 parameters that were used to analyse the
36 intervention descriptions and the definition of each is provided as follows:

- 37 1) Approachability parameter included information exploring the ability of participants to perceive
38 risk about the available support services, recruitment process and personalised risk assessment.
- 39 2) Acceptability parameter assessed the ability to seek information through social and cultural
40 factors determining participation in interventions, such as the use of translator services, sociocultural
41 training for staff as well as translating materials into native languages.

1 3) Availability assessed the ability to reach wider communities for participation in the intervention,
 2 including ability to use technology and transportation considerations.

3 4) Affordability assessed any costs associated with SACT treatment and whether indirect costs were
 4 considered when designing an intervention.

5 5) Appropriateness parameter was used to assess patient's engagement and empowerment to make
 6 informed decisions during interventions.

7

8 **Results**

9 Search results

10 The initial search of the databases yielded 1356 articles of which 106 were taken to abstract review
 11 following removal of duplicates (n=41) (Figure 2). 1209 articles were removed after title screen,
 12 which was performed by researcher (JM) with a 10% validation performed by researcher (LS). Full
 13 abstract review was performed by two researchers (JM, LS). 41 articles were excluded after the
 14 abstract screening stage leaving 65 articles for full review. Following the application of inclusion and
 15 exclusion criteria by both authors, seven studies were included in analysis and quality assessment.
 16 An additional, two studies were identified through citation searches, resulting in a total of nine
 17 studies included in this scoping review. Mixed Methods Appraisal Tool (MMAT) was used to assess
 18 the overall quality of the studies and the overall score provided in table 3. The detailed analysis of
 19 the quality of studies are summarised in Appendix 4 [23]. To explore types of interventions the
 20 template of intervention description and Republication checklist was adapted and used to analyse
 21 data [Appendix 3] [22].

22

23 Table 2. Participant and design characteristics of studies in the scoping review (n = 9).

24

Study characteristics	Number (n)
Cancer type:	
Breast	n=7
Multiple	n=1
Breast and Lung	n=1
Sample size (range)	n=24-1442
Participant age (range)	n=45-63
Study design:	
RCT	n=3
NRCT	n=1
Mixed Methods study	n=1
Randomised pilot study	n=3
Non-Randomised pilot study	n=1
Intervention type:	
In person	n=2
Digital	n=6
Hybrid (Digital/In person)	n=1
Stage of cancer:	
I	n=5
II	n=0
III	n=0
IV	n=0
Any stage	n=4
Ethnicity of participants:	

African Americans	n=7
Asian Americans	n=1
Hispanic/Latino	n=1

1

2 Description of interventions designed to optimise experience with SACT for people from MEG

3 Key characteristics of the studies were summarised in table 2. There was much heterogeneity within
 4 the study populations and outcomes for the nine included studies. Interestingly, all the studies were
 5 conducted in the United States of America (USA) with a wide range of sample sizes, including studies
 6 with 24 participants and larger studies recruiting 1442. Studies employed different designs to deliver
 7 interventions and were carried out by various healthcare professionals, often race matched (n=5)
 8 with the participants in the studies. The length of the studies ranged from a single two-hour
 9 workshop intervention (n=1) to studies supporting patients through care navigation and highlighting
 10 missed appointments to providers over a 5-year period (n=1). Seven different categories of outcome
 11 variables were examined across the 9 studies: medication adherence (n=2), health literacy (n=1),
 12 completion of treatment (n=1), self-efficacy (n=2), quality of life (n=2), survivorship experience (n=1),
 13 feasibility of an intervention (n=2).

14 Digital interventions versus in-person and hybrid interventions

15 Of the nine studies, six interventions were conducted digitally, two were delivered in person and
 16 another study incorporated mixed mode of delivery. (Appendix 3) The majority of interventions used
 17 technology to optimise patients' experiences with SACT. There were only two studies that assessed
 18 quality of life of participants and both of them showed no effect post intervention [24,25]. The rest
 19 of the four digital studies had positive outcomes, including improved completion rates of treatment
 20 [26] and high satisfaction with the programme's content on the websites [27,28]. Randomised pilot
 21 study conducted by Perez et. al reported moderate-to-high levels of positive emotional reactions to
 22 stories and identification with storytellers.[29] Digital interventions used different approaches to
 23 reach participants in their studies. Two of the studies designed culturally tailored virtual
 24 programmes, available on their websites [27,28], three studies employed interactive videos showing
 25 race-matched survivor stories [24,25, 29] and further digital study used electronic record system that
 26 would flag up missed appointments or unmet milestones in patient's treatment. [30]

27 Out of two in-person delivered interventions, one did not show an effect on health literacy,
 28 medication adherence or self-efficacy from pre-test to post intervention. [30]. Another in person
 29 delivered study was a feasibility trial and reported increased self-efficacy in communicating with
 30 providers and self-efficacy in making treatment decisions. [31]

31 An intervention conducted by Rosenzweig et.al. incorporated supportive video messages from the
 32 African American community as well as in person training in their design. This hybrid study reported
 33 a positive effect of a psychoeducational session with race-matched interventionist delivering training
 34 sessions. [32]

35

36

37

38 Equity assessment of interventions designed to optimise experience with SACT for people from MEG

1 People from MEG were the focus population of the nine studies, where participants were mainly
2 recruited from urban locations (n=7), 17 community oncology practices (n=1) and online (n=1). All of
3 the studies incorporated culturally targeted materials in their design, ranging from guidebooks, print
4 materials and decision-making models. There were several similarities across the studies, such as
5 identification of the need to race match the recruiter with study participants [30,32], recognising the
6 importance of translating educational materials into native languages [24,28] as well as providing
7 staff with racial equity training [25,26,29].

8 Interventions were analysed using the equity framework as reported by Sayani et al. [5],
9 incorporating different accessibility dimensions such as approachability, acceptability, availability,
10 affordability, and appropriateness in people from MEG. (Table 4) All the interventions suggested that
11 approachability to SACT could be enhanced through raising awareness and recruiting participants
12 from different geographic locations, including both online and offline strategies.

13 Acceptability of interventions was reported in all but one study [30], which did not incorporate
14 neither cultural staff training, translation of materials into other languages or tailoring intervention
15 to personal and cultural values of participants. Only four interventions considered the availability of
16 SACT across people from MEG, as they did not rely on participants ability to use technology, and
17 recruitment was not dependent on prior engagement with the health care system.[24-27,] Three of
18 the nine interventions took into account affordability of SACT, by reimbursing patients for taking part
19 in intervention, the rest six interventions did not mention direct or indirect costs associated with
20 participation in a study. [25,30,31]. Finally, all but four interventions attempted to incorporate the
21 appropriateness of SACT services by increasing levels of engagement and promoting informed
22 decision-making. [26,28,30-32] No intervention in this scoping review incorporated all five
23 dimensions of the equity framework. Language barriers were addressed in studies by Im et.al and Loi
24 et.al., as participants' native languages were Asian and Spanish, respectively.

25 Table 3. Overview of included studies detailing interventions to improve experiences and clinical outcomes in
26 people from MEG receiving SACT treatments

27
28
29
30
31
32
33
34

Author, year, country	Intervention delivery mode	Objectives	Methods	Sample Demographics	Outcomes	Quality assessment
Rust, 2015, USA [30]	In person Medication adherence skills training (MST) workshop	To explore what was the level and role of health literacy, with respect to medication adherence and self-efficacy.	Randomised pilot study	African American breast cancer survivors within one year of treatment from three urban areas of a Southeastern, Tennessee State (n=48)	Questionnaires were administered to measure patient self-efficacy in medication usage, medication adherence, and a three question measure for health literacy. Intervention did not show a statistically significant effect on health literacy (HL), medication adherence or self-efficacy. Statistically significant relationship was found between the initial HL and medication adherence.	3
Rosenzweig, 2011, USA [32]	Hybrid (in person and digital) Psychoeducational one to one intervention	To test the effect of an intervention on treatment adherence.	Randomised pilot study	African American breast cancer women receiving first adjuvant therapy from two urban sites of the Comprehensive Breast Program in the University of Pittsburgh Cancer Institute, a National Cancer Institute (n=24)	45-minute face-to-face meeting with intervention participants was recorded and adherence rates to chemotherapy were measured at three time points corresponding to treatment completion: 50%, 75%, and 100%. Results demonstrated more rapid initiation of chemotherapy and better overall adherence to chemotherapy.	2
Cykert, 2019, USA [26]	Digital Real time registry combined with feedback	To improve the treatment completion rates of surgery, recommended radiation and chemotherapy for each patient.	Non-randomised controlled trial (NRCT)	African American and White ethnic group patients with early stage lung and breast cancers at two cancer centres (n=302)	African American patients in the intervention group achieved a Treatment Complete rate of 88.4% compared to 89.5% for White ethnic group (p = 0.77).	1
Loi, 2016, USA [24]	Digital Self-administered stress management training	To examine the efficacy of a culturally and linguistically tailored training in improving QOL and reducing psychological distress.	Randomised controlled trial (RCT)	Hispanic/Latino patients newly diagnosed with cancer from 17 local community oncology practices across the U.S. and Puerto Rico (n=219)	No significant treatment effects on quality of life and reducing psychological distress were demonstrated. Improved mental health scores were observed with patients on a psychotropic agent (p=.04).	2

Turbes, 2015, USA ^[27]	Digital Web-Based Programme using interviews, online screener and post-use survey	To assess implementation and fidelity of an intervention.	Mixed-method study	African American women age <45 with breast cancer from three cancer centres (n=1442)	75% of post-use survey respondents were very or somewhat satisfied with the web-based programme; 70% of respondents said the web-based programme content was somewhat or very useful.	1
Sheppard, 2013, USA ^[31]	In person Peer-Led decision support intervention	To assess the acceptability of the intervention.	Non-randomised pilot study	African American women over 21 years old diagnosed with any stage breast cancer from Washington, DC metropolitan area (n=76)	Participants reported increased self-efficacy in communicating with providers (70 %) and self-efficacy in making treatment decisions (70 %).	2
Perez, 2020, USA ^[29]	Digital Interactive cancer-communication video program	To examine the feasibility and acceptability of an interactive video program.	Randomised pilot study	African American women newly diagnosed with breast cancer from three cancer centres (n=107)	104 of 108 patients allocated to the intervention reported moderate-to-high levels of positive emotional reactions to stories and identification with storytellers.	1
Thompson, 2021, USA ^[25]	Digital Viewing survivor stories	To determine whether viewing survivor stories improved newly diagnosed African American breast cancer patients' QOL.	Randomised controlled trial (RCT)	African American women with breast cancer from three cancer centres (n=228)	No effect of study arm on QOL, depressive symptoms, or concerns about recurrence was found in this study.	1
Im, 2023, USA ^[28]	Digital Virtual program using social media sites, interactive online educational sessions and online resources	To determine the efficacy of a culturally tailored virtual information and coaching/support program in improving patients survivorship experience.	Randomised controlled trial (RCT)	Asian American women within 5 years of the diagnosis from online and offline cancer support groups (n=199)	Women were asked to fill out the questionnaires at different points during 12 week study period. Results showed that intervention group had a significant increase in their quality of life.	2

1 *Key to quality assessments: 1-Good, 2-Average, 3-Poor

2 Quality assessment/Critical appraisal of individual sources of evidence

3 Only one study [30] did not meet MMAT criteria and therefore was scored as a 3. Another four studies have met the criteria at 60-80%, thus were given a score of 2. The remaining four studies have met the MMAT criteria at 80-100% and were rated as good quality studies with a score of 1.

2 Table 4. Accessibility dimensions identified in interventions targeting people in MEG receiving SACT^[5]

Author, year, country	Positive impacts (Intended and/or Unintended)	Negative impacts (Intended and/or Unintended)	Dimensions of accessibility
Rust, 2015, USA ^[30]	Approachability: Participants were recruited by the staff of a community-based organisation for underserved and minority women diagnosed with breast cancer, helping participants to engage and connect with the study personnel. Affordability: All participants were compensated for participation with gift cards at the beginning and end of the study, however costs of transportation or treatment were not discussed in the study. Appropriateness: Patients were able to engage with a licensed pharmacist and social worker during two-hour workshop exploring medication usage and adherence.	Acceptability: Translational services were not mentioned in the study. Only the possibility of an oral questionnaire delivery was suggested. Availability: Even though participants for this intervention were recruited from three urban locations, increasing its availability to reach several communities, the sample size was small, included only 48 patients with a very specific set of characteristics, therefore reducing the chances of taking part in the intervention for those individuals who were beyond first year of breast cancer treatment path. Participants were recruited through contacts with American Cancer Society or through community-based organisation, limiting its reach to patients from other organisations.	Approachability \checkmark Acceptability \times Availability \times Affordability \times Appropriateness \checkmark
Rosenzweig, 2011, USA ^[32]	Approachability: Race-matched recruiters were used during recruitment phase of the study. Acceptability: The interventionist was an African American breast cancer survivor. Appropriateness: Patients were provided with 1:1 supportive session discussing attitudes (including perceptions and stressors) that may affect adherence to clinical visits and treatment.	Availability: Patients were recruited from two University of Pittsburgh Cancer Institute clinics, thus limiting the participation in this intervention for wider communities. Affordability: Consideration of cost was mentioned only as limitation in this study. Cost to retain an interventionist on staff needs to be assessed to determine whether the intervention can be integrated into routine clinical practice.	Approachability \checkmark Acceptability \checkmark Availability \times Affordability \times Appropriateness \checkmark
Cykert, 2019, USA ^[26]	Approachability: multi-faceted approach utilizing transparency of clinical data and care team accountability achieved through race-specific audit and feedback was required for the highest probability of success. Acceptability: Nurse and physician were specially trained in teach - back technique, anti-racism, and to advocate for patients. Availability: Study spanned over 5 years and nurse navigators have applied their special anti-racial training to all patients. Appropriateness: all patients were engaged in the study by trained personnel	Affordability: Cost implications of treatment or transportation were not mentioned, apart from a grant from The National Cancer Institute that was used to fund the study.	Approachability \checkmark Acceptability \checkmark Availability \checkmark Affordability \times Appropriateness \checkmark
Loi, 2016, USA ^[24]	Approachability: patients received targeted intervention. Acceptability: Community experts and a certified translator were consulted for the initial adaptation and translation of English materials. Availability: patients were recruited from 17 community practices, thus expanding the pool of participants significantly.	Affordability: The costs of treatment or transportation were not accounted in the study. Appropriateness: 5-minute, standardized explanation of the nature and purpose of the intervention was provided. Patients were instructed to view the video/DVD first and to follow the directions in the booklet to better understand the training, practice and use of stress management techniques.	Approachability \checkmark Acceptability \checkmark Availability \checkmark Affordability \times Appropriateness \times

Turbes, 2015, USA [27]	<p>Approachability: Participants received reproductive and psychosocial information and support using various platforms during the study.</p> <p>Acceptability: Materials of the intervention were culturally appropriate for the target population.</p> <p>Availability: intervention was provided via multiple channels, including web and social media.</p>	<p>Affordability: Ability to pay indirect costs such as transportation not covered</p> <p>Appropriateness: This intervention was highly reliant on technology, assuming that participants have access to internet and social media. Also this type of intervention does not engage patients to high extent in the decision making about their treatment.</p>	<p>Approachability \diamond</p> <p>Acceptability \diamond</p> <p>Availability \diamond</p> <p>Affordability \times</p> <p>Appropriateness \times</p>
Sheppard, 2013, USA [31]	<p>Approachability: Women with histologically confirmed breast cancer were recruited from the Washington, DC area</p> <p>Acceptability: The coach used a culturally appropriate guidebook and decision-making model—TALK Back!</p> <p>Appropriateness: Peer-delivered culturally relevant decision support intervention for Black women with breast cancer.</p> <p>Affordability: Ability to pay indirect costs such as transportation not covered.</p> <p>Participants received a grocery store gift card.</p>	<p>Availability: Patients were recruited mainly from cancer surgeons.</p>	<p>Approachability \diamond</p> <p>Acceptability \diamond</p> <p>Availability \times</p> <p>Affordability \times</p> <p>Appropriateness \diamond</p>
Perez, 2020, USA [29]	<p>Approachability: Intervention arm completed a baseline/pre-intervention interview, received the video intervention, and completed a post-intervention 1-month follow-up interview.</p> <p>Acceptability: Intervention was conducted by specially trained study team coordinators.</p>	<p>Availability: Patients were recruited from their breast surgeons</p> <p>Affordability: Ability to pay indirect costs such as transportation not covered</p> <p>Appropriateness: Patients received a brief (~10 minute) in-person training to use the video program plus an instructional user guide to take home.</p>	<p>Approachability \diamond</p> <p>Acceptability \diamond</p> <p>Availability \times</p> <p>Affordability \times</p> <p>Appropriateness \times</p>
Thompson, 2021, USA [25]	<p>Approachability: African American women with non-metastatic breast cancer interviewed five times over two years.</p> <p>Acceptability: The video used in the intervention was culturally adapted to the participants.</p> <p>Availability: Participants of the study were interviewed five times over a period of two years, intervention was reliant on ability to use tablet or computer</p> <p>Affordability: Ability to pay indirect costs such as transportation not covered.</p> <p>Participants received \$25 per interview.</p>	<p>Appropriateness: Patients were instructed to watch videos and understand and interpret their content in their own homes.</p>	<p>Approachability \diamond</p> <p>Acceptability \diamond</p> <p>Availability \diamond</p> <p>Affordability \times</p> <p>Appropriateness \times</p>
Im, 2023, USA [28]	<p>Approachability: Support programme was created for Asian-American women with breast cancer</p> <p>Acceptability: The content of interventional material was culturally tailored to Asian-American women (intervention components that were provided in five languages (English, Mandarin Chinese [Simplified and Traditional], Korean, and Japanese)</p> <p>Appropriateness: The social media sites provided a medium by which participants could connect to each other and share their own breast cancer survivor experience with peers.</p>	<p>Availability: The intervention group utilized American Cancer Society [ACS] website to deliver intervention</p> <p>Affordability: Ability to pay indirect costs such as transportation not covered</p>	<p>Approachability \diamond</p> <p>Acceptability \diamond</p> <p>Availability \times</p> <p>Affordability \times</p> <p>Appropriateness \diamond</p>

1 Discussion

2 This was the first scoping review of its kind investigating interventions to optimise SACT treatments in
3 people with cancer from MEG. The review showed the breadth of interventions that have been
4 researched that could have the potential to improve patient experience, self-efficacy when making
5 decisions related to SACT and adherence. Our searches found only a small number of studies in total,
6 with differing outcome measures. Studies developed were focussed on digital interventions that
7 were either offering holistic support to patients or educational materials. Comparing digital versus in-
8 person delivered interventions showed that there was no difference in one mode of delivery
9 superseding another, where equity related provisions were considered. Interventions that were most
10 effective in improving access to SACT used variety of approaches, ensuring the design of the study
11 integrated wide range of accessibility parameters, such as approachability, acceptability, availability,
12 affordability, and appropriateness of the studies. We adapted an existing equity framework [6] to
13 assess patients' from MEG experiences during their SACT treatments. Our results suggested that
14 structural and social determinants of health were interconnected and highlighted the importance of
15 incorporating these equity considerations when developing interventions. It was surprising that
16 none of the studies were conducted outside of the USA. The UK population is 18% from MEG and
17 therefore inclusive cancer care would benefit 1 in 5 patients. [33] Another unexpected finding was
18 that none of the studies had assessed the economic impact of interventions, which is essential for
19 health care researchers, policy makers and providers to make informed decisions.

20 The majority of studies were describing interventions in early breast cancer – a finding that is not
21 surprising as breast cancer is among the top three cancers globally, affecting 2.26 million women and
22 is the leading cause of cancer mortality worldwide [34]. There are multiple factors behind disparities
23 that are affecting global cancer survival rates and it is one of the World Health Organisations' (WHO)
24 priorities to improve survival across the world. Breast cancer patients are being offered a
25 comprehensive treatment and supportive care, but still adherence issues are very common and
26 understood to have health economic implications [35]. Non-adherence to prescribed medications is
27 associated with poor therapeutic outcomes, progression of disease and overall healthcare costs.
28 Improvement in adherence can help in reducing the economic burden in long-term and improve
29 cost-effectiveness [36]. Significant economic barriers to cancer services still exist and people from
30 MEG are impacted by structural vulnerability, combining factors such as poverty, homelessness and
31 racism. Research indicates the populations that experience socioeconomic disadvantage more likely
32 to experience delays in starting SACT treatment, are less likely to receive any treatment and have
33 poor adherence rates to systemic therapy. Interestingly, results of this scoping review show that
34 digital interventions were chosen as a preferred method of conveying information to people from
35 MEG, suggesting that there is access to technology and capacity to be able to self-manage their care
36 needs and navigate a complex care system. [37]

37 Following the Covid-19 pandemic there have been an increased number of virtually delivered
38 healthcare interactions [38,39] and they are still being used daily in current practice worldwide,
39 albeit mostly in high-income countries. Digital interventions reduce costs associated with
40 appointment scheduling and can reduce travel time for patients to cancer centres, thus translating
41 into increased patient satisfaction with their care. Virtual coaching and digital support programmes
42 could potentially change health behaviours and as a result improve health outcomes amongst
43 vulnerable cancer patients. However, using telehealth as a means of providing healthcare services to
44 people with cancer from MEG could be also seen as another potential avenue for widening inequity
45 among cancer patients, as low and middle-income countries should be able to benefit from it too
46 [40].

1 One previous systematic review by Hayanga et. al [41] suggested that for some people from MEG
2 with multiple long-term conditions in the United Kingdom there may be inadequate initiatives for
3 managing health conditions and that there is a need for enhanced strategies to reduce ethnic
4 inequalities in healthcare. Wider societal processes such as suboptimal healthcare provision together
5 with individual cancer patients' from MEG journey (with additional barriers, such as language
6 difficulties and poor literacy skills) can have negative impact on people's ability to access and utilise
7 healthcare services effectively.

8 Another study by Unruh et.al, comparing health policy responses to COVID-19 highlighted that there
9 needs to be a universal investment across the health sector physical infrastructure and training to
10 reduce unmet care needs and health inequalities among the most vulnerable population groups.
11 [42]. Interventions to reduce health inequity should be directed at downstream determinants of
12 health, such as individual health-care needs, midstream determinants, such as neighbourhood
13 conditions, or upstream determinants, such as structural racism and discrimination. There are several
14 theoretical approaches to social determinants of health with ethnicity and racism falling under a
15 social disadvantage approach. Greater social disadvantage is associated with poorer health and more
16 research is needed to clarify the underlying pathways.

17 This study has identified gaps in the design of interventions targeted at people from MEG
18 populations and a new equity-framework was tested for patients undergoing SACT. Future
19 interventions exploring the relationship among minority patient groups may use this framework as a
20 useful tool in their equity assessments to improve access to SACT across all at-risk groups and reduce
21 inequalities in cancer care.

22 Study Limitations

23 This is the only study of its kind that we are aware of, utilising a systematic methodology including
24 quality appraisal by two researchers, incorporation of an equity-based framework and intervention
25 reporting guidelines. Despite this, there were very few studies that met our inclusion criteria, and we
26 were limited by small sample sizes. By nature, scoping reviews capture the breadth of literature in
27 the area and therefore our studies were heterogeneous in the methods used. This scoping review
28 maps out the currently available literature on interventions in people with cancer from MEG and
29 highlights the need for further adequately powered interventional studies. Future work should focus
30 on further evaluation of SACT services provided in cancer centres, starting with a local context
31 assessment and review of policies.

32 Conclusions

33 The key findings were that published evaluations of interventions to optimise SACT management in
34 people from MEG are limited to early breast cancer patients, predominantly of African-American
35 background, and that studies were mainly conducted in high-income countries, such as USA in
36 particular. **We found evidence of interventions incorporating the equity domains that reported**
37 **improved patient engagement and experience.** This new knowledge will help to implement future
38 SACT interventions, addressing health inequities across the cancer continuum and explore future
39 directions in patient navigation to promote equitable care. Healthcare providers should view the
40 equity considerations identified in this review as unique perceptions of people from MEG undergoing
41 SACT treatment rather than obstacles in providing cancer care. The future research should focus on
42 psychosocial and cultural influences to help design effective equitable interventions.

43

1 Key messages

2

3 1. Evaluations of interventions to optimise SACT management in people from MEG are limited
4 to African American early breast cancer patients.
5 2. All studies were conducted in high-income countries, such as USA.
6 3. Interventions that incorporated equity domains into their design had positive impact on
7 patient experience with SACT.
8 4. The future research should focus on psychosocial and cultural influences to help design
9 effective equitable interventions.

10

11

References

12 1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and
13 trends—an update. *Cancer epidemiology, biomarkers & prevention*. 2016 Jan 1;25(1):16-27.
14 DOI: [10.1158/1055-9965.EPI-15-0578](https://doi.org/10.1158/1055-9965.EPI-15-0578)

15 2. Singh GK, Jemal A. Socioeconomic and racial/ethnic disparities in cancer mortality, incidence,
16 and survival in the United States, 1950–2014: over six decades of changing patterns and
17 widening inequalities. *Journal of environmental and public health*. 2017
18 Oct;2017. DOI: [10.1155/2017/2819372](https://doi.org/10.1155/2017/2819372)

19 3. Patel MI, Ferguson JM, Castro E, Pereira-Estremera CD, Armaiz-Peña GN, Duron Y, Hlubocky F,
20 Infantado A, Nuqui B, Julian D, Nortey N. Racial and ethnic disparities in cancer care during
21 the COVID-19 pandemic. *JAMA network open*. 2022 Jul 1;5(7):e2222009-.
22 DOI: [10.1001/jamanetworkopen.2022.22009](https://doi.org/10.1001/jamanetworkopen.2022.22009)

23 4. Patel MI, Lopez AM, Blackstock W, Reeder-Hayes K, Moushey EA, Phillips J, Tap W. Cancer
24 disparities and health equity: a policy statement from the American Society of Clinical
25 Oncology. *Journal of Clinical Oncology*. 2020 Oct 10;38(29):3439-48.
26 DOI: [10.1200/JCO.20.00642](https://doi.org/10.1200/JCO.20.00642)

27 5. Sayani A, Ali MA, Dey P, Corrado AM, Ziegler C, Nicholson E, Lofters A. Interventions designed
28 to increase the uptake of lung cancer screening: an equity-oriented scoping review. *JTO*
29 6. Szczepura A, Price C, Gumber A. Breast and bowel cancer screening uptake patterns over 15
30 years for UK south Asian ethnic minority populations, corrected for differences in socio-
31 demographic characteristics. *BMC public health*. 2008 Dec;8:1-5. doi: 10.1186/1471-2458-8-
32 346.

33 7. Clinical and Research Reports. 2023 Mar 1;4(3):100469. DOI: [10.1016/j.itocrr.2023.100469](https://doi.org/10.1016/j.itocrr.2023.100469)
34 Trends in the global medicines market 2024. GHP PDIG Symposium, 20th June 2024. IQVIA
35 Institute for Human Data Science. Global Outlook to 2028, May 2024. Available from:
36 www.iqviainstitute.org. Accessed [17/9/2024]

37 8. Greer JA, Amoyal N, Nisotol L, Fishbein JN, MacDonald J, Stagl J, Lennes I, Temel JS, Safran
38 SA, Pirl WF. A systematic review of adherence to oral antineoplastic therapies. *The
39 oncologist*. 2016 Mar 1;21(3):354-76.

40 9. McGuinness S, Hughes L, Moss-Morris R, Hunter M, Norton S, Moon Z. Adherence to
41 adjuvant endocrine therapy among White British and ethnic minority breast cancer
42 survivors in the United Kingdom. *European Journal of Cancer Care*. 2022 Nov;31(6):e13722.

43 10. Cancer incidence statistics. Available at: < Cancer incidence statistics | Cancer Research UK>
44 Accessed on 22.04.24

1 11. Verbrugghe M, Verhaeghe S, Lauwaert K, Beeckman D, Van Hecke A. Determinants and
2 associated factors influencing medication adherence and persistence to oral anticancer
3 drugs: a systematic review. *Cancer treatment reviews*. 2013 Oct 1;39(6):610-21.
4 DOI: [10.1016/j.ctrv.2012.12.014](https://doi.org/10.1016/j.ctrv.2012.12.014)

5 12. Papadakos JK, Hasan SM, Barnsley J, Berta W, Fazelzad R, Papadakos CJ, Giuliani ME, Howell
6 D. Health literacy and cancer self-management behaviors: A scoping review. *Cancer*. 2018
7 Nov 1;124(21):4202-10. DOI: [10.1002/cncr.31733](https://doi.org/10.1002/cncr.31733)

8 13. Gast A, Mathes T. Medication adherence influencing factors—an (updated) overview of
9 systematic reviews. *Systematic reviews*. 2019 Dec;8:1-7. DOI: [10.1186/s13643-019-1014-8](https://doi.org/10.1186/s13643-019-1014-8)

10 14. Berkman ND, Davis TC, McCormack L. Health literacy: what is it?. *Journal of health
communication*. 2010 Aug 31;15(S2):9-19. DOI: [10.1080/10810730.2010.499985](https://doi.org/10.1080/10810730.2010.499985)

11 15. Hyde JE. Reconsidering Health Literacy: The Role of Implicit Bias. Temple University; 2017.

12 16. Vela MB, Erondu AI, Smith NA, Peek ME, Woodruff JN, Chin MH. Eliminating explicit and
13 implicit biases in health care: evidence and research needs. *Annual review of public health*.
2022 Apr 5;43(1):477-501. DOI: [10.1146/annurev-publhealth-052620-103528](https://doi.org/10.1146/annurev-publhealth-052620-103528)

14 17. Vaccarella S, Georges D, Bray F, Ginsburg O, Charvat H, Martikainen P, Brønnum-Hansen H,
15 Deboosere P, Bopp M, Leinsalu M, Artnik B. Socioeconomic inequalities in cancer mortality
16 between and within countries in Europe: a population-based study. *The Lancet Regional
Health—Europe*. 2023 Feb 1;25. DOI: [10.1016/j.lanepe.2022.100551](https://doi.org/10.1016/j.lanepe.2022.100551)

17 18. Arksey H, O'malley L. Scoping studies: towards a methodological framework. *International
journal of social research methodology*. 2005 Feb 1;8(1):19-32. doi
18 [10.1080/1364557032000119616](https://doi.org/10.1080/1364557032000119616)

19 19. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MD, Horsley T,
20 Weeks L, Hempel S. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and
21 explanation. *Annals of internal medicine*. 2018 Oct 2;169(7):467-73. DOI: [10.7326/M18-0850](https://doi.org/10.7326/M18-0850)

22 20. BMJ Best Practice. How to clarify a clinical question [Internet]. [cited 2024 Jan 15]. Available
23 from: [https://bestpractice.bmj.com/info/us/toolkit/learn-ebm/how-to-clarify-a-clinical-
question/](https://bestpractice.bmj.com/info/us/toolkit/learn-ebm/how-to-clarify-a-clinical-
question/)

24 21. McDonagh M, Peterson K, Raina P, Chang S, Shekelle P. Avoiding bias in selecting studies.
25 Methods guide for effectiveness and comparative effectiveness reviews [Internet]. 2013 Feb
26 20. PMID: 23487864

27 22. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, Altman DG, Barbour V,
28 Macdonald H, Johnston M, Lamb SE. Betterof interventions: template for intervention
29 description and replication (TIDieR) checklist and guide. *Bmj*. 2014 Mar 7;348. doi:
30 [10.1136/bmj.g1687](https://doi.org/10.1136/bmj.g1687) (www.equator-network.org/reporting-guidelines/tidier/)

31 23. Hong QN, Fabbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, Gagnon MP, Griffiths F,
32 Nicolau B, O'Cathain A, Rousseau MC. The Mixed Methods Appraisal Tool (MMAT) version
33 2018 for information professionals and researchers. *Education for information*. 2018 Jan
34 1;34(4):285-91. doi 10.3233/EFI-180221

35 24. Loi CX, Nesman TM, Xu P, Taylor TR, McMillan S, Krischer JP, Tyc VL, Gross-King M, Huegel V.
36 A self-administered stress management intervention for hispanic patients undergoing
37 cancer chemotherapy. *Journal of Immigrant and Minority Health*. 2017 Oct;19:1121-31.
38 DOI: [10.1007/s10903-016-0524-x](https://doi.org/10.1007/s10903-016-0524-x)

39 25. Thompson T, Pérez M, Yan Y, Kreuter MW, Margenthaler JA, Colditz GA, Jeffe DB.
40 Randomized controlled trial of a breast cancer Survivor Stories intervention for African
41 American women. *Social Science & Medicine*. 2021 Feb 1;270:113663.
42 DOI: [10.1016/j.socscimed.2020.113663](https://doi.org/10.1016/j.socscimed.2020.113663)

43

44

45

46

47

48

1 26. Cykert S, Eng E, Manning MA, Robertson LB, Heron DE, Jones NS, Schaal JC, Lightfoot A,
2 Zhou H, Yongue C, Gizlice Z. A multi-faceted intervention aimed at Black-White disparities in
3 the treatment of early stage cancers: the ACCURE pragmatic quality improvement trial.
4 Journal of the National Medical Association. 2020 Oct 1;112(5):468-77.
5 DOI: [10.1016/j.jnma.2019.03.001](https://doi.org/10.1016/j.jnma.2019.03.001)

6 27. Johnson-Turbes A, Schlueter D, Moore AR, Buchanan ND, Fairley TL. Evaluation of a web-
7 based program for African American young breast cancer survivors. American journal of
8 preventive medicine. 2015 Dec 1;49(6):S543-9. DOI: [10.1016/j.amepre.2015.09.003](https://doi.org/10.1016/j.amepre.2015.09.003)

9 28. Im EO, Chee W, Paul S, Choi MY, Kim SY, Deatrick JA, Inouye J, Ma G, Meghani S, Nguyen GT,
10 Schapira MM. A randomized controlled trial testing a virtual program for Asian American
11 women breast cancer survivors. Nature Communications. 2023 Oct 14;14(1):6475.
12 DOI: [10.1038/s41467-023-42132-6](https://doi.org/10.1038/s41467-023-42132-6)

13 29. Pérez M, Kreuter MW, Yan Y, Thompson T, Sefko J, Golla B, Margenthaler JA, Colditz G, Jeffe
14 DB. Feasibility and acceptability of an interactive cancer-communication Video program
15 using African American breast cancer survivor stories. Journal of health communication.
16 2020 Jul 2;25(7):566-75. DOI: [10.1080/10810730.2020.1821132](https://doi.org/10.1080/10810730.2020.1821132)

17 30. Rust CF, Davis C, Moore MR. Medication adherence skills training for African-American
18 breast cancer survivors: the effects on health literacy, medication adherence, and self-
19 efficacy. Social work in health care. 2015 Jan 2;54(1):33-46.
20 DOI: [10.1080/00981389.2014.964447](https://doi.org/10.1080/00981389.2014.964447)

21 31. Sheppard VB, Wallington SF, Willey SC, Hampton RM, Lucas W, Jennings Y, Horton S, Muzeck
22 N, Cocilovo C, Isaacs C. A peer-led decision support intervention improves decision
23 outcomes in black women with breast cancer. Journal of Cancer Education. 2013
24 Jun;28:262-9. DOI: [10.1007/s13187-013-0459-z](https://doi.org/10.1007/s13187-013-0459-z)

25 32. Rosenzweig M. The attitudes, communication, treatment, and support intervention to
26 reduce breast cancer treatment disparity. Number 1/January 2011. 2011 Jan 1;38(1):85-9.
27 DOI: [10.1188/11.ONF.85-89](https://doi.org/10.1188/11.ONF.85-89)

28 33. [Ethnicity facts and figures. Goverment data about the UK's different ethnic groups. Available at: < Ethnicity facts and figures – GOV.UK \(ethnicity-facts-figures.service.gov.uk\)>](#) [Accessed
29 on 24/09/2024].

30 34. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F.
31 Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and
32 methods. International journal of cancer. 2019 Apr 15;144(8):1941-53.
33 DOI: [10.1002/ijc.31937](https://doi.org/10.1002/ijc.31937)

34 35. Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. The British
35 journal of radiology. 2022 Feb 1;95(1130):20211033. DOI: [10.1259/bir.20211033](https://doi.org/10.1259/bir.20211033)

36 36. Gupta J, Joshi P, Kamra S, Sehgal M. Economic Burden due to Treatment Non-Adherence in
37 Patients with Breast Cancer: A Systematic Review. Value in Health. 2016 May 1;19(3):A156.
38 Doi: [10.1063/jval.2016.03.1461](https://doi.org/10.1063/jval.2016.03.1461)

39 37. Bourgeois A, Horrill TC, Mollison A, Lambert LK, Stajduhar KI. Barriers to cancer treatment
40 and care for people experiencing structural vulnerability: a secondary analysis of
41 ethnographic data. International Journal for Equity in Health. 2023 Mar 30;22(1):58.
42 DOI: [10.1186/s12939-023-01860-3](https://doi.org/10.1186/s12939-023-01860-3)

43 38. Chow MC, Chambers P, Singleton G, Patel J, Cooper S, Mythen C, Bautista-González E,
44 Chisnall G, Djellouli N, Thwaites B, Wong IC. Global changes to the chemotherapy service
45 during the covid-19 pandemic. Journal of Oncology Pharmacy Practice. 2021 Jul;27(5):1073-
46 9. DOI: [10.1177/10781552211015767](https://doi.org/10.1177/10781552211015767)

1 39. Dalby M, Hill A, Nabhani-Gebara S. Cancer patient experience of telephone clinics
2 implemented in light of COVID-19. *Journal of Oncology Pharmacy Practice*. 2021
3 Apr;27(3):644-9. DOI: [10.1177/1078155221990101](https://doi.org/10.1177/1078155221990101)

4 40. Doraiswamy S, Abraham A, Mamtani R, Cheema S. Use of telehealth during the COVID-19
5 pandemic: scoping review. *Journal of medical Internet research*. 2020 Dec 1;22(12):e24087.
6 DOI: [10.2196/24087](https://doi.org/10.2196/24087)

7 41. Hayanga B, Stafford M, Becares L. Ethnic inequalities in healthcare use and care quality
8 among people with multiple long-term health conditions living in the United Kingdom: a
9 systematic review and narrative synthesis. *International Journal of Environmental Research
and Public Health*. 2021 Nov 29;18(23):12599. doi: 10.3390/ijerph182312599.

10 42. Unruh L, Allin S, Marchildon G, Burke S, Barry S, Siersbaek R, Thomas S, Rajan S, Koval A,
11 Alexander M, Merkur S. A comparison of 2020 health policy responses to the COVID-19
12 pandemic in Canada, Ireland, the United Kingdom and the United States of America. *Health
Policy*. 2022 May 1;126(5):427-37. DOI: [10.1016/j.healthpol.2021.06.012](https://doi.org/10.1016/j.healthpol.2021.06.012)

15

16 Figure 1. Equity-orientated SACT intervention considerations for patients from MEG.

17 Figure 2. Prisma flow diagram

18

19

20

21